

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/023,275	STEINERT ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Jennifer I. Harle	1654	

**All Participants:**

**Status of Application:** \_\_\_\_\_

(1) Jennifer I. Harle.

(3) \_\_\_\_\_.

(2) Nancy Vensko.

(4) \_\_\_\_\_.

**Date of Interview:** 20 September 2004

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No  
 If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

17

Prior art documents discussed:

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*Amending claim 17 so that the oxyhexadecanoic acid would be properly incorporated. The attorney authorized amending the Claim 17 to substitute comprising in place of is.*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

\_\_\_\_\_  
 (Applicant/Applicant's Representative Signature – if appropriate)

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Nancy Vensko on September 20, 2004.

The application has been amended as follows:

17. (Currently Amended) The composition of Claim 6, wherein said synthetic omega-hydroxyceramide comprises is 16-(16-hydroxyhexadecyl)oxyhexadecanoic acid.

### *Reasons for Allowance*

The previous rejections are withdrawn in light of Applicants' amendments to the claims and arguments, which now disclose TGase1 and a synthetic lipid vesicle comprising omega-hydroxyceramide, including Applicants' arguments that the combination provides for unexpected results in activity of the TGase1, i.e. the TGase I enzyme attaches ceramides to proteins, thus resulting in attaching the omega-hydroxyceramide to the various skin proteins for use in treatment of the skin. See page 11 of the Amendment filed December 13, 2001.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer I. Harle whose telephone number is (571) 272-2763. The examiner can normally be reached on Monday through Thursday, 6:30 am to 5:00 pm,.

Art Unit: 1654

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jennifer Ione Harle  
September 22, 2004



**MICHAEL MELLER**  
**PRIMARY EXAMINER**